False-positive rifampicin resistance on Xpert® MTB/RIF: Case report and clinical implications

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 2, 2012, Pages 206-208

  Van Rie, Annelies ^a   Mellet, K ^b   John, M A ^c,d   Scott, L ^c,d   Page Shipp, L ^b   Dansey, H ^e   Victor, T ^f   Warren, R ^f  

^a IL   (United States)

^b RIGHT TO CARE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e Witkoppen Health and Welfare Centre   (South Africa)

^f STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Assay performance; False positive rifampicin resistance; MDR TB; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM DETECTION; CASE REPORT; CD4 LYMPHOCYTE COUNT; COUGHING; DISEASE DURATION; DNA SEQUENCE; DRUG RESISTANT TUBERCULOSIS; FALSE POSITIVE RESULT; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHA GENE; LABORATORY TEST; MALE; MICROSCOPY; MIXED INFECTION; MOLECULAR PROBE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE; SEQUENCE ANALYSIS; SPOLIGOTYPING; SPUTUM SMEAR; TREATMENT DURATION; WILD TYPE; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS, ANTITUBERCULAR; DIAGNOSIS, DIFFERENTIAL; DNA, BACTERIAL; FALSE POSITIVE REACTIONS; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84855712719     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0395     Document Type: Article

References (10)

1. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. WHO/HTM/TB/2011.2. Geneva, Switzerland: WHO, 2011.
2. Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
3. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
4. Johnson R, Streicher E M, Louw G E, Warren R M, van Helden P D, Victor T C. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8: 97-111.
5. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914. (Pubitemid 27146535)
6. Marlowe E M, Novak-Weekley S M, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011; 49: 1621-1623.
7. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184: 132-140.
8. Boehme C. Feasibility and impact of using Xpert MTB/RIF: results from demonstration studies. Geneva, Switzerland: Foundation for Innovative New Diagnostics, 2010. http://www.finddiagnostics.org/export/sites/default/resource- centre/presentations/iualtd-41st-union-conf-berlin-2010-FIND-Forum/ CatharinaBoehme-FeasibilityAndImpact.pdf Accessed December 2011.
9. Lawn S D, Brooks S V, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicine resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8: e1001067.
10. Hoek K G, Schaaf H S, Gey van Pittius N C, van Helden P D, Warren R M. Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. S Afr Med J 2009; 99: 785-787.